DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Relenza (Zanamivir) - Summary



The active component of RELENZA is zanamivir, an antiviral agent.

RELENZA is indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days (see Description of Clinical Studies and PRECAUTIONS).

RELENZA is not recommended for treatment of patients with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) (see WARNINGS and PRECAUTIONS).
See all Relenza indications & dosage >>


Media Articles Related to Relenza (Zanamivir)

Bird Flu (Avian Influenza, Avian Flu)
Source: MedicineNet Aches, Pain, Fever Specialty [2015.03.19]
Title: Bird Flu (Avian Influenza, Avian Flu)
Category: Diseases and Conditions
Created: 10/25/2005 12:00:00 AM
Last Editorial Review: 3/19/2015 12:00:00 AM

Key to blocking influenza virus may lie in a cell's own machinery
Source: Flu / Cold / SARS News From Medical News Today [2015.02.17]
Viruses are masters of outsourcing, entrusting their fundamental function - reproduction - to the host cells they infect. But it turns out this highly economical approach also creates vulnerability.

Institute for Glycomics combats human parainfluenza virus
Source: Flu / Cold / SARS News From Medical News Today [2015.02.14]
Gold Coast research has made a giant leap forward in understanding one of the most common causes of respiratory infections worldwide.

Low influenza vaccination rates among nursing home employees put residents at risk, study finds
Source: Caregivers / Homecare News From Medical News Today [2015.01.29]
Influenza is associated with as many as 7,300 deaths annually in nursing home residents, but the vaccination rate for nursing home staff is only 54 percent, according to a study in the American...

Study maps travel of H7 influenza genes
Source: Bird Flu / Avian Flu News From Medical News Today [2015.01.25]
Influenza has a long history of being one of the most deadly diseases to afflict humanity, but what exactly makes it so dangerous?

more news >>

Published Studies Related to Relenza (Zanamivir)

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. [2010.11.02]
CONCLUSIONS: In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy. Despite the theoretical potential for the reduction of the emergence of antiviral resistance, the lower effectiveness of this combination calls for caution in its use in clinical practice. TRIAL REGISTRATION: www.ClinicalTrials.govNCT00799760.

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. [2008.01]
OBJECTIVE: To compare the effectiveness of zanamivir with oseltamivir for influenza A and B... CONCLUSION: Zanamivir therapy is more effective than oseltamivir for the treatment of influenza B infection.

Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. [2007.08]
Background: Influenza can cause significant morbidity and mortality in subjects at high risk for complications, including the elderly (age >/=65 years) and those with chronic respiratory, cardiovascular, or metabolic conditions...

Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. [2003.06]
Influenza is an important cause of hospitalization due to lower respiratory tract involvement for which there is no specific antiviral treatment with proven efficacy. We conducted a double-blind, randomized, placebo-controlled trial to assess the tolerability and efficacy of nebulized zanamivir (16 mg four times a day) in combination with rimantadine compared to rimantadine with nebulized saline for treating influenza in adults hospitalized with influenza...

Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. [2003]
A randomized, double-blind, placebo-controlled, parallel-group trial performed at 5 residential units of the Finnish Defence Forces was conducted to assess the antiviral activity, efficacy and safety of inhaled zanamivir for the treatment of naturally acquired influenza... Zanamivir rapidly reduced viral load following the start of therapy compared with placebo and was well tolerated.

more studies >>

Clinical Trials Related to Relenza (Zanamivir)

Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir [Not yet recruiting]
In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks. Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir. The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2.

A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects [Terminated]
This study is a 4 period study to see if there is any interaction between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects

Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults [Recruiting]
Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it. Other reliable methods of treating H5N1 must be identified in case of a pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The primary purpose of this study is to evaluate the interaction between oral oseltamivir and intravenous zanamivir administered as either a continuous or intermittent infusion in healthy adults.

A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection [Recruiting]
The outbreak of respiratory illnesses in Mexico that began in March 2009 was caused by a swine origin influenza A (H1N1) virus (S-OIV) that had not been recognized previously in pigs or humans. As of 17 May 2009, 39 countries have officially reported 8480 cases of influenza A (H1N1) infection.

The H1N1 influenza A virus appears sensitive to oseltamivir and zanamivir in vitro, but resistant to amantadine and rimantadine. This study is to test the oseltamivir, zanamivir and placebo arms as the first line treatment for human swine influenza infection. Through the study, the investigators may have better understanding about the clinical and, biochemical, virological profiles of oseltamivir/zanamivir on the H1N1 virus, and optimizing the treatment strategy among the Chinese population.

Zanamivir Versus Trivalent Split Virus Influenza Vaccine [Not yet recruiting]
This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers.

The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.

more trials >>

Reports of Suspected Relenza (Zanamivir) Side Effects

Abnormal Behaviour (40)Hallucination (17)Delirium (17)Aggression (12)Screaming (10)Loss of Consciousness (8)Nausea (8)Convulsion (8)Depressed Level of Consciousness (8)Pyrexia (7)more >>

Page last updated: 2015-03-19

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015